Junshi Bio's anti-CD112R monoclonal antibody was approved for clinical use in the United States

On April 3, Junshi Bio announced that the company's self-developed anti-CD112R monoclonal antibody injection (project code: TAB009/JS009) has been approved by the US FDA for a clinical trial application for the treatment of advanced solid tumors

CD112R, also known as PVRIG (poliovirus receptor-associated immunoglobulin domain), is a single-transmembrane protein of the PVR family, mainly expressed on T cells and NK cells, and significantly up-regulated after cell activation

JS009 is a recombinant humanized IgG4 monoclonal antibody targeting CD112R independently developed by Junshi Bio for the treatment of advanced malignant tumors

It is worth noting that TIGIT is another immunosuppressive target of the PVR family, and its ligands have PVR and CD112, and its binding site for CD112 is different from CD112R

Junshi Bio stated in a press release that the results of preclinical studies showed that the anti-CD112R monoclonal antibody TAB009/JS009, anti-TIGIT monoclonal antibody TAB006/JS006 and the anti-PD-1 monoclonal antibody developed by Junshi Biotechnology were injected with toripalimab.

References:

[1] Good news | Junshi Bio’s JS009 (anti-CD112R monoclonal antibody) clinical trial application was approved by the US FDA.